{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:15:43Z","timestamp":1760908543913},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1097\/mjt.0b013e3181d5ae5d","type":"journal-article","created":{"date-parts":[[2010,5,11]],"date-time":"2010-05-11T06:52:03Z","timestamp":1273560723000},"page":"e1-e11","source":"Crossref","is-referenced-by-count":1,"title":["Newer Anticoagulants as an Alternate to Warfarin in Atrial Fibrillation: A Changing Paradigm"],"prefix":"10.1097","volume":"18","author":[{"given":"Dhara","family":"Chaudhari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Bhuriya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210202","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/01.STR.28.6.1101","article-title":"Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators.","volume":"28","author":"Feinberg","year":"1997","journal-title":"Stroke"},{"key":"R2-9-20210202","first-page":"1449","article-title":"Analysis of pooled data from five randomized controlled trials [published erratum appears in Arch Intern Med. 1994;154:2254].","volume":"154","year":"1994","journal-title":"Arch Intern Med"},{"key":"R3-9-20210202","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0140-6736(87)90174-7","article-title":"Risk of stroke in non-rheumatic atrial fibrillation [published erratum appears in Lancet. 1987;1:878].","volume":"1","author":"Flegel","year":"1987","journal-title":"Lancet"},{"key":"R4-9-20210202","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"R5-9-20210202","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1161\/01.CIR.99.23.3028","article-title":"Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists.","volume":"99","author":"Levy","year":"1999","journal-title":"Circulation"},{"key":"R6-9-20210202","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/archinte.1987.00370090041008","article-title":"Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study.","volume":"147","author":"Wolf","year":"1987","journal-title":"Arch Intern Med"},{"key":"R7-9-20210202","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0002-9343(99)80348-9","article-title":"The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study.","volume":"98","author":"Krahn","year":"1995","journal-title":"Am J Med"},{"key":"R8-9-20210202","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-131-9-199911020-00010","article-title":"Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention.","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"R9-9-20210202","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1001\/jama.1994.03510350050036","article-title":"Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.","volume":"271","author":"Benjamin","year":"1994","journal-title":"JAMA"},{"key":"R10-9-20210202","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/archinte.1990.00390220082016","article-title":"Epidemiologic features of asymptomatic cerebral infarction in patients with nonvalvular atrial fibrillation.","volume":"150","author":"Feinberg","year":"1990","journal-title":"Arch Intern Med"},{"key":"R11-9-20210202","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1161\/01.STR.19.8.955","article-title":"Asymptomatic cerebral infarction in patients with chronic atrial fibrillation.","volume":"19","author":"Kempster","year":"1988","journal-title":"Stroke"},{"key":"R12-9-20210202","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1161\/01.CIR.84.2.933","article-title":"Stroke Prevention in Atrial Fibrillation Study. Final results.","volume":"84","year":"1991","journal-title":"Circulation"},{"key":"R13-9-20210202","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1161\/01.STR.18.6.1098","article-title":"Silent cerebral infarction in chronic atrial fibrillation.","volume":"18","author":"Petersen","year":"1987","journal-title":"Stroke"},{"key":"R14-9-20210202","first-page":"1979","article-title":"ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of patients with Atrial Fibrillation).","volume":"27","author":"Fuster","year":"2006","journal-title":"Eur Heart J"},{"key":"R15-9-20210202","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMp0903763","article-title":"Left atrial appendage occlusion-closure or just the beginning?","volume":"360","author":"Maisel","year":"2009","journal-title":"N Engl J Med"},{"key":"R16-9-20210202","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.","volume":"293","year":"2005","journal-title":"JAMA"},{"key":"R17-9-20210202","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/eurheartj\/ehm575","article-title":"New Oral anticoagulants in atrial fibrillation.","volume":"29","author":"Turpie","year":"2007","journal-title":"Eur Heart J"},{"key":"R18-9-20210202","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial.","volume":"362","author":"Olsson","year":"2003","journal-title":"Lancet"},{"key":"R19-9-20210202","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archinte.167.3.239","article-title":"Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.","volume":"167","author":"White","year":"2007","journal-title":"Arch Intern Med"},{"key":"R20-9-20210202","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R21-9-20210202","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin dabigatran etexilate.","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R22-9-20210202","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"R23-9-20210202","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1177\/1076029609343004","article-title":"Pharmacology, pharmacokinetics, and pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor.","volume":"15","author":"Stangier","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"key":"R24-9-20210202","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMra044440","article-title":"Direct Thrombin Inhibitors.","volume":"353","author":"Di Nisio","year":"2005","journal-title":"N Engl J Med"},{"key":"R25-9-20210202","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","article-title":"Pharmacokinetics and pharmacodynamics of the direct thrombin inhibitor dabigatran in healthy elderly subjects.","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R26-9-20210202","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1538-7836.2004.01100.x","article-title":"A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.","volume":"3","author":"Eriksson","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R27-9-20210202","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the Re-model randomized trial.","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R28-9-20210202","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial.","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"R29-9-20210202","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.amjcard.2007.06.034","article-title":"Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvaivular atrial fibrillation (PETRO Study).","volume":"100","author":"Ezekowitz","year":"2007","journal-title":"Am J Cardiol"},{"key":"R30-9-20210202","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"R31-9-20210202","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1538-7836.2009.03298.x","article-title":"The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from phase III clinical trials.","volume":"7","author":"Veyrat-Follet","year":"2009","journal-title":"J Thromb Haemost"},{"key":"R32-9-20210202","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(08)60168-3","article-title":"Comparison of idraparinux with Vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomized, open label, non-inferiority trial.","volume":"371","author":"Amadeus Investigators, Bousser","year":"2008","journal-title":"Lancet"},{"key":"R33-9-20210202","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1538-7836.2007.02436.x","article-title":"A phase II study of the oral factor Xa inhibitor LY5 17717 for the prevention of venous thromboembolism after hip or knee replacement.","volume":"5","author":"Agnelli","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R34-9-20210202","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1182\/blood.V108.11.911.911","article-title":"Biochemical and pharmacological profiles of YM150, an oral direct Factor Xa inhibitor.","volume":"108","author":"Iwatsuki","year":"2006","journal-title":"Blood"},{"key":"R35-9-20210202","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/j.1538-7836.2007.02644.x","article-title":"Lassen MR, et al; ONYX study group. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery.","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R36-9-20210202","first-page":"288A","article-title":"A Phase I study to assess the antithrombotic properties of DU-176b: an orally active direct factor Xa inhibitor (Abstract).","volume":"47","author":"Zafar","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R37-9-20210202","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1538-7836.2008.02939.x","article-title":"Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.","volume":"6","author":"Wong","year":"2008","journal-title":"J Thromb Haemost"},{"key":"R38-9-20210202","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","article-title":"The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.","volume":"5","author":"Lassen","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R39-9-20210202","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1538-7836.2008.03054.x","article-title":"Investigators, Writing Committee, Buller H, et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.","volume":"6","year":"2008","journal-title":"J Thromb Haemost"},{"key":"R40-9-20210202","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement.","volume":"361","author":"Lassen","year":"2009","journal-title":"N Engl J Med"},{"key":"R41-9-20210202","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood.V108.11.901.901","article-title":"Animal models of thrombosis help predict the human therapeutic concentration of PRT54021, a potent oral factor Xa inhibitor.","volume":"108","author":"Abe","year":"2006","journal-title":"Blood"},{"key":"R42-9-20210202","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1160\/TH08-07-0460","article-title":"A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).","volume":"101","author":"Turpie","year":"2009","journal-title":"Thromb Haemost"},{"key":"R43-9-20210202","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1177\/0091270007302952","article-title":"Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet induced thrombin generation and prothrombinase activity.","volume":"47","author":"Graff","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R44-9-20210202","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct factor Xa inhibitor.","volume":"3","author":"Perzborn","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R45-9-20210202","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1055\/s-2007-982083","article-title":"Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.","volume":"33","author":"Laux","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"R46-9-20210202","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1185\/03007990802361499","article-title":"Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects.","volume":"24","author":"Kubitza","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"R47-9-20210202","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R48-9-20210202","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/0091270006292127","article-title":"Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban-an oral, direct factor Xa inhibitor-are not affected by aspirin.","volume":"46","author":"Kubtiza","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R49-9-20210202","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/00002018-200831010-00006","article-title":"Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.","volume":"31","author":"Kubitza","year":"2008","journal-title":"Drug Saf"},{"key":"R50-9-20210202","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/0091270006296058","article-title":"Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban(BAY 59-7939) in healthy subjects.","volume":"47","author":"Kubitza","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R51-9-20210202","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"The treatment of proximal deep vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep Vein Thrombosis)Study.","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"key":"R52-9-20210202","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","article-title":"A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.","volume":"112","author":"Buller","year":"2008","journal-title":"Blood"},{"key":"R53-9-20210202","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/j.1538-7836.2005.01602.x","article-title":"Bay 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.","volume":"3","author":"Turpie","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R54-9-20210202","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1302\/0301-620X.91B5.21691","article-title":"Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.","volume":"91","author":"Eriksson","year":"2009","journal-title":"J Bone Joint Surg Br"},{"key":"R55-9-20210202","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"R56-9-20210202","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomized trial.","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"R57-9-20210202","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS TIMI 46): a randomized, double-blind, phase II trial.","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"R59-9-20210202","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial.","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"R60-9-20210202","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ageing\/afl129","article-title":"A randomized controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO).","volume":"36","author":"Rash","year":"2007","journal-title":"Age Ageing"},{"key":"R61-9-20210202","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1161\/01.STR.30.6.1223","article-title":"Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators.","volume":"30","author":"Hart","year":"1999","journal-title":"Stroke"},{"key":"R62-9-20210202","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/01.STR.28.5.1015","article-title":"Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators.","volume":"28","author":"Morocutti","year":"1997","journal-title":"Stroke"},{"key":"R63-9-20210202","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jacc.2004.05.084","article-title":"Comparative effects of antiplatelet, antithrombotic, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study.","volume":"44","author":"Perez-Gomez","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R64-9-20210202","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation.","volume":"360","author":"The Active Investigators, Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"R65-9-20210202","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","article-title":"Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.","volume":"118","author":"Connolly","year":"2008","journal-title":"Circulation"},{"key":"R66-9-20210202","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000118380","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.","volume":"25","author":"Hart","year":"2008","journal-title":"Cerebrovasc Dis"},{"key":"R67-9-20210202","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/eurheartj\/ehm274","article-title":"An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.","volume":"28","author":"Wang","year":"2007","journal-title":"Eur Heart J"},{"key":"R68-9-20210202","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(96)03487-3","article-title":"Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial.","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"R69-9-20210202","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/archinte.159.12.1322","article-title":"Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation.","volume":"159","author":"Gullov","year":"1999","journal-title":"Arch Intern Med"},{"key":"R70-9-20210202","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1345\/aph.1K591","article-title":"Aspirin, clopidogrel, and warfarin: Is the combination appropriate and effective or inappropriate and too dangerous?","volume":"42","author":"Hermosillo","year":"2008","journal-title":"Ann Pharmacother"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0b013e3181d5ae5d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:35:45Z","timestamp":1620963345000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201101000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3181d5ae5d","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}